Korean Biotech Opens Mass. Office

Xconomy Boston — 

OCT USA, a U.S. unit of Korean biotech firm Osteogenic Core Technologies, plans to open an office in Cambridge, MA, today, the Boston Globe reports. The Globe says that OCT—which is developing treatments for osteoporosis and arthritis—plans to hire 30 scientists in Cambridge and pump $8 million to $10 million into its new operation at One Kendall Square over the next three years.